VP, DM1 Commercial Asset Lead

Our commitment to people with neuromuscular diseases

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at  , and follow us on X , Linked In and Facebook .

The VP, DM1 Commercial Asset Lead (CAL) is a passionate driver of the value of Dyne’s DM1 commercial asset with a global perspective, bringing adaptable leadership to develop and implement commercialization strategies that maximize reach and value creation within the neuromuscular portfolio.

This mandate includes market analysis, competitive positioning, launch readiness and execution, and input into lifecycle management to support long‑term success in bringing the asset to patients globally. The CAL is a highly visible leadership role and, as a key member of the Program Team, works cross‑functionally to influence and help shape Program strategy.

The CAL leads the definition of commercialization strategy, strategic imperatives, critical success factors, executional priorities, and global launch planning in close partnership with affiliate launch teams. This role balances a forward‑looking orientation toward broad global access for patients with a pragmatic approach to planning, risk mitigation, and execution. The CAL collaborates with Program Team members, functional leads, and affiliate teams to achieve a differentiated product profile, competitive label, broad reimbursement, and successful global launches, starting with the U.S.

As a member of the Program Team, the CAL is responsible for advancing commercialization readiness and works in strong partnership with the Program Lead, Head of Commercialization, functional leaders, and affiliate launch teams.

This role is based onsite in Waltham, MA.

• Define global asset commercialization strategy and plan to achieve milestones and timelines for successful launches
• Shape competitive positioning, differentiation strategy, and overall value proposition
• Provide commercialization input into program strategy, including label and access considerations
• Establish strategic imperatives, critical success factors, and execution priorities

• Lead global launch planning and readiness across key markets, starting with the U.S.
• Partner with cross‑functional teams (medical, regulatory, supply, marketing, digital, data) to prepare for launch execution
• Collaborate with affiliate teams and external partners to support reimbursement and access readiness
• Drive continuous improvement and learning across markets

• Serve as a key member of the Program Team and lead the DM1 Commercial Sub‑Team
• Ensure alignment across commercialization pillars (product profile, access, launch planning)
• Facilitate cross‑functional decision‑making and drive timely outcomes
• Build strong partnerships across functions and maintain clear communication with leadership

• Build a credible and visible presence within the DM1 community, including KOLs, patient advocacy groups, and care teams
• Maintain awareness of competitive landscape and evolving market dynamics
• Support preparation and presentation of commercialization materials for senior leadership and Board discussions
• Participate in business development activities, including opportunity evaluation and due diligence, as needed

• Bachelor’s degree in a relevant scientific, medical, or business discipline required; advanced degree strongly preferred
• Minimum of 20 years of experience in the biopharmaceutical industry
• 15+ years of commercialization and cross‑functional leadership experience
• Exte…